Tag
The PANDA II study demonstrates that influenza vaccination significantly reduces mortality and rehospitalization in acute heart failure patients, supporting its inclusion as a standard component of heart failure management worldwide.
The DIGIT-HF trial sheds new light on digitoxin’s role in heart failure with reduced ejection fraction, revealing safety, efficacy, and clinical implications despite contemporary therapies.
The REST trial demonstrated that combining isatuximab with weekly bortezomib, lenalidomide, and limited dexamethasone yields promising efficacy and manageable safety in older patients with transplant-ineligible multiple myeloma.
A phase 3a trial shows coadministered cagrilintide and semaglutide (CagriSema) significantly reduce body weight up to 20.4% over 68 weeks in adults with overweight or obesity, with manageable side effects, offering a promising new option fo
Rentosertib, an AI-designed TNIK inhibitor, demonstrated safety and preliminary efficacy in idiopathic pulmonary fibrosis in a randomized phase 2a trial, marking a milestone in AI-driven drug development for progressive lung diseases.
CPL’116, a novel dual JAK and ROCK inhibitor, demonstrates dose-dependent efficacy and a favorable safety profile in rheumatoid arthritis patients inadequately responsive to methotrexate, without the typical lipid or creatine kinase a
The TUSCANY-2 phase 2b trial evaluated afimkibart, a novel anti-TL1A antibody, in moderately-to-severely active ulcerative colitis, demonstrating favorable safety and clinically meaningful remission rates using modified Mayo scores despite
The ORCA-3 trial confirms cytisinicline’s efficacy and safety for smoking cessation at 6 and 12 weeks, showing sustained abstinence and reduced nicotine craving up to 24 weeks.
A large randomized clinical trial demonstrates that pulmonary rehabilitation using minimal equipment is noninferior to gym-based programs with specialist equipment for improving exercise capacity and quality of life in chronic respiratory d
This trial assessed the additive effects of low-dose transdermal estrogen replacement therapy combined with resistance exercise in women aged 65+ with knee osteoarthritis, finding no overall significant benefit but suggesting potential impr
HTD1801 (berberine ursodeoxycholate) significantly improves liver histology and reduces fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) as demonstrated by preclinical models and a Phase 2 trial.
The SAPPHIRE phase 3 trial found that adding apitegromab to nusinersen or risdiplam produced a small but statistically significant improvement in motor function in children aged 2–12, with a safety profile similar to placebo.
A phase 3 trial demonstrates that a telephone-based lifestyle intervention achieves clinically significant weight loss in women with stage II/III breast cancer and overweight/obesity, with notable effectiveness across demographics, especial
Inhaled molgramostim, a recombinant human GM-CSF, significantly improves lung gas transfer and quality of life in autoimmune pulmonary alveolar proteinosis, with safety comparable to placebo.
A randomized clinical trial found that exenatide infusion during and after cardiopulmonary bypass did not reduce death or major organ failure in low-risk patients undergoing coronary artery bypass grafting or aortic valve replacement.
A phase 4 randomized trial demonstrates that combining rabies monoclonal antibody with vaccine in category 3 exposures is safe, immunogenic, and effective in preventing rabies up to one year post-exposure.
The VOYAGE phase 2 trial demonstrated that etrasimod, an oral S1P receptor modulator, significantly reduces oesophageal eosinophilic inflammation and improves endoscopic findings in adults with eosinophilic oesophagitis, with a favorable sa
The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818
This study demonstrates the superior effectiveness of remote monitoring in reducing blood pressure among hypertensive patients compared to usual care and self-monitoring.
The SOGALDI-PEF trial evaluates the effects of dapagliflozin combined with spironolactone versus dapagliflozin alone in patients with heart failure, revealing significant improvements in NT-proBNP levels and safety concerns.
